S-TACE联合阿帕替尼对中晚期原发性肝癌患者肿瘤血管因子、肝功能和预后的影响

肝脏 ›› 2020, Vol. 25 ›› Issue (9): 933-936.

S-TACE联合阿帕替尼对中晚期原发性肝癌患者肿瘤血管因子、肝功能和预后的影响

徐新宝, 殷杰, 吉浩明, 钱俐

226600 南通大学附属海安医院普外科(徐新宝,殷杰,吉浩明);南通大学附属医院肿瘤科(钱俐)

出版日期:2020-09-30 发布日期:2020-10-22
通讯作者: 徐新宝,Email:949184758@qq.com
基金资助:
南通市2017年度市级科技计划项目(MS12017017)

Effects of S-TACE combined with apatinib on tumor vascular factors, liver function and prognosis in patients with advanced primary liver cancer

XU Xin-bao¹,YIN Jie¹, JI Hao-ming¹, QIAN Li²

1. Department of General Surgery, Hai'an Hospital Affiliated to Nantong University, Jiangsu 226600, China;
2. Department of Oncology, Affiliated Hospital of Nantong University, Jiangsu 226600, China

Online:2020-09-30 Published:2020-10-22
Contact: XU Xin-bao, Email:949184758@qq.com

摘要/Abstract

摘要： 目的探讨对中晚期原发性肝癌(HCC)患者采用超选择性肝动脉化疗栓塞术(S-TACE)联合阿帕替尼治疗的效果和安全性。方法将近年来的72例中晚期HCC患者分成两组,对照组采用S-TACE治疗,观察组采用S-TACE联合阿帕替尼治疗;观察两组的肿瘤血管炎症因子、肝功能的变化,治疗效果和安全性指标。结果治疗前,两组的VEGFR2、MMP-9和caspase-8等肿瘤血管因子指标水平,以及AFP-L3、ALT和LDH等肝功能指标水平比较,无统计学意义(P>0.05);疗程结束后,观察组的肿瘤血管因子和肝功能指标水平均较对照组改善,有统计学意义(P<0.05)。观察组的ORR和DCR高于对照组,MTTP和MOS大于对照组,有统计学意义(P<0.05)。两组的栓塞后综合征比较无统计学意义(P>0.05);观察组的药物不良反应高于对照组,有统计学意义(P>0.05)。结论对中晚期HCC 患者采用S-TACE联合阿帕替尼治疗,可抑制肿瘤血管再生,改善肝脏功能,提高临床获益率,安全性较高。

关键词: 原发性肝癌, S-TACE, 阿帕替尼, 肿瘤血管因子, 安全性

Abstract: Objective To investigate the efficacy and safety of super-selective hepatic arterial chemoembolization (S-TACE) combined with apatinib in patients with advanced primary liver cancer (HCC). Methods In recent years, 72 patients with advanced HCC were divided into two groups. The control group was treated with S-TACE, and the observation group was treated with S-TACE combined with apatinib. The changes of tumor vascular inflammatory factors, liver function, therapeutic effect and safety indexes in the two groups were observed. Results Before treatment, the levels of tumor vascular factors such as VEGFR2, mmp-9 and caspase-8, as well as the levels of liver function indexes such as AFP-L3,ALT ,and LDH in the two groups were not statistically significant (P>0.05). After the treatment, the levels of tumor vascular factors and liver function indexes in the observation group were improved compared with those in the control group, which was statistically significant (P<0.05). The ORR and DCR in the observation group were higher than those in the control group, while MTTP and MOS were higher than those in the control group, which was statistically significant (P<0.05). There was no significant difference in the postembolization syndrome between the two groups (P>0.05). The adverse drug reactions in the observation group were higher than those in the control group, which was statistically significant (P>0.05). Conclusion For patients with advanced HCC, S-TACE combined with apatinib therapy can inhibit tumor angiogenesis, improve liver function, improve clinical benefit rate and provide high safety.

Key words: Primary liver cancer, S-TACE, Apatinib, Tumor vascular factor, security

徐新宝, 殷杰, 吉浩明, 钱俐. S-TACE联合阿帕替尼对中晚期原发性肝癌患者肿瘤血管因子、肝功能和预后的影响[J]. 肝脏, 2020, 25(9): 933-936.

XU Xin-bao,YIN Jie, JI Hao-ming, QIAN Li. Effects of S-TACE combined with apatinib on tumor vascular factors, liver function and prognosis in patients with advanced primary liver cancer[J]. Chinese Hepatolgy, 2020, 25(9): 933-936.

参考文献

[1] Rowe IA, Sherman M. Capitalising on improved rates of diagnosis ofearly hepatocellular carcinoma. J Hepatol, 2016, 64(2): 260-261.
[2] 张萌,薛挥,张向东,等.微导管超选择性栓塞化疗治疗中晚期原发性肝癌的临床观察.肝脏,2019,24(5):592-593.
[3] 李威,满文玲,郭欢庆,等.TACE 联合甲磺酸阿帕替尼治疗中晚期肝癌的临床研究.肿瘤药学,2017,7(1):74-78.
[4] 王雅婕,胡毅.甲磺酸阿帕替尼治疗晚期恶性肿瘤的研究进展.解放军医学院学报,2018,39(6):542-545.
[5] 国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版).中华肝脏病杂志,2020,27(2):112-128.
[6] 翁志成,彭建扬,吴伟达,等.阿帕替尼联合S-TACE治疗中晚期原发性肝癌的疗效及安全性评价.癌症进展,2019,17(22):2666-2669.
[7] 曹非.TACE联合甲磺酸阿帕替尼治疗中晚期肝细胞肝癌的临床研究.天津:天津医科大学,2019.
[8] Varghese J, Kedarisetty C, Venkataraman J, et al. Combination of TACE and sorafenib improves outcomes in BCLC stages B/C of hepatocellular carcinoma: asingle centre experience. Ann Hepatol, 2017, 16(2): 247-254.
[9] 黎莹,杨冬阳,赖晓嵘,等.阿帕替尼联合TACE对肝癌患者AFP、VEGF和CEA的影响.肝脏,2018,23(5):426-430.
[10] 杨庆,潘松松,施昌盛,等.甲磺酸阿帕替尼联合TACE治疗中晚期肝癌的效果及对患者血清VEGF和MMP-9的影响.中华介入放射学,2019,7(2):111-116.
[11] 吴发宗,吕秀玲,宋晶晶,等.阿帕替尼联合肝动脉化疗栓塞术的抗肝癌疗效及对肿瘤血管再生的影响.温州医科大学学报,2019,49(6):423-426.
[12] 吴彦彦.经肝动脉化疗栓塞术联合阿帕替尼对中晚期原发性肝癌患者血清甲胎蛋白异质体的影响.中医药临床杂志,2019,31(4):736-738.
[13] Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med, 2018,7(9): 4570-4583.
[14] 温时来.阿帕替尼治疗晚期肝癌的疗效及血清LDH水平变化观察.药品评价,2019,49(20):68-69.
[15] 叶岩荣,曹畅,钟凯龙,等.阿帕替尼治疗中晚期肝癌疗效与安全性的系统评价.中国临床药学杂志,2020,29(2): 129-135.
[16] 胡猛,刘星,刘静,等.阿帕替尼治疗恶性肿瘤研究进展.中国老年学杂志,2018,38(19): 4858-4861.